Northland Capmk Has Positive View of Brainsway Q3 Earnings

Key Points

• Northland Capital Markets has increased its Q3 2025 earnings estimates for Brainsway, projecting earnings per share of $0.10, up from a previous estimate of $0.06.
• Brainsway reported earnings of $0.10 per share for the last quarter, exceeding analyst expectations of $0.07 and generating revenue of $12.63 million.
• Analysts have differing views on Brainsway, with Northland Securities upgrading their price target to $19.00, while Wall Street Zen downgraded the stock from a "buy" to a "hold" rating.

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) - Equities researchers at Northland Capmk lifted their Q3 2025 earnings per share (EPS) estimates for Brainsway in a note issued to investors on Wednesday, August 13th. Northland Capmk analyst C. Byrnes now forecasts that the company will earn $0.10 per share for the quarter, up from their prior estimate of $0.06. The consensus estimate for Brainsway's current full-year earnings is $0.08 per share. Northland Capmk also issued estimates for Brainsway's FY2026 earnings at $0.40 EPS.

A number of other research analysts have also recently weighed in on the stock. HC Wainwright raised their price objective on shares of Brainsway from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Brainsway from a "hold" rating to a "buy" rating in a research report on Sunday. Finally, Northland Securities upped their price target on shares of Brainsway from $15.00 to $19.00 and gave the company an "outperform" rating in a research report on Thursday, August 14th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Brainsway currently has an average rating of "Buy" and an average target price of $18.00.

Brainsway Price Performance

Shares of BWAY stock traded down $0.38 during midday trading on Friday, reaching $14.47. 87,142 shares of the company traded hands, compared to its average volume of 54,003. The firm's 50 day simple moving average is $12.15 and its two-hundred day simple moving average is $10.56. Brainsway has a 1-year low of $7.06 and a 1-year high of $15.00. The firm has a market cap of $273.48 million, a PE ratio of 55.66 and a beta of 1.42.

Brainsway (NASDAQ:BWAY - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.07 by $0.03. Brainsway had a return on equity of 8.97% and a net margin of 11.60%.The firm had revenue of $12.63 million for the quarter, compared to analyst estimates of $12.34 million. Brainsway has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Brainsway

A number of large investors have recently modified their holdings of BWAY. Lazard Asset Management LLC bought a new position in Brainsway during the 4th quarter worth $44,000. Raymond James Financial Inc. purchased a new position in Brainsway in the second quarter valued at about $85,000. GAMMA Investing LLC raised its holdings in Brainsway by 720.7% during the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock valued at $89,000 after acquiring an additional 8,216 shares during the period. Palumbo Wealth Management LLC bought a new stake in Brainsway during the 1st quarter valued at $111,000. Finally, Trexquant Investment LP bought a new position in shares of Brainsway in the 1st quarter worth $129,000. Institutional investors and hedge funds own 30.11% of the company's stock.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.